In 2007, the CIN started with 25 principal investigators as cluster applicants, as stipulated in the DFG call for bids. When the CIN cluster was approved further scientists from a range of institutions were incorporated, to make up the 48 'founding members' of the CIN. Since the beginning of 2014 the CIN has consisted of over 80 scientists in total. The membership process involves an application to the steering committee in which the candidate outlines his or her scientific profile and submits a list of publications. The committee's decision is based purely on the scientific excellence of each candidate.
Prof. Dr. Thomas Gasser
Organization: Hertie Institute for Clinical Brain Research / DZNE Tübingen
Phone number: +49 (0)7071 29 86529
Department: Dept. for Neurodegenerative Diseases
Area: CIN Staff
Scientific topic: Biomarkers of Parkinson's disease
Field of Research
To identify markers for an earlier diagnosis and disease progression in Parkinson's disease (PD). Large genome wide association studies are being done to define risk as well as protecitve markers for the disease. In large prospective cohort studies risk and premotor markers are assessed. Subjects are followed longitudinally to define the relative risk and predictive value of the respective markers. Similarly longitudinal follow up of motor and non-motor symptoms in cohorts of PD patients in different stages are done to define the best suitable progression markers for better validation of treatment strategies. A special focus is put on the definition premotor and progression markers in monogenetic PD. Biomaterial including DNA, RNA, CSF and fibroblast is stored in a large biobank for determination of biomarkers. Findings will be translated into our animal models for better understanding of the pathophysiology and development of therapeutic strategies.
genome-wide association studies (GWAS), linkage studies, genotyping, LRRK2 transgenic mouse model system, primary cell culture, induced pluripotent stem (iPS) cells, biobanking, functional neuroimaging, MRI, transcranial sonography, ambulatory sleep recording, neuropsychological testing, quantitatvie sensory and autonomic testing, accelerometry, determination of olfaction
biomarkers; brain imaging; clinical neurosciences; degeneration / regeneration; neuro-genetics; neurology; neuronal stem cells
- Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2009). Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 41(12):1308-12.
- Maetzler W, Liepelt I, Berg D (2009). Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol. 8(12):1158-71.
- Liepelt I, Behnke S, Schweitzer K, Wolf B, Godau J, Wollenweber F, et al. (2009). Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging. [Epub ahead of print]